Orionis Biosciences BV has established a multiyear collaboration with Genentech Inc., a member of the Roche Group, to discover novel small-molecule molecular glues for targets in major disease areas, including oncology and neurodegeneration.

Peptidream Inc. has entered into a new multitarget collaboration and license agreement with Genentech, a member of the Roche Group, focused on the discovery and development of novel macrocyclic peptide-radioisotope drug conjugates.

Benevolentai Ltd. has signed a strategic collaboration with Merck KGaA to identify novel drug candidates, initially for three targets in oncology, neurology and immunology.

Evaxion Biotech A/S has announced the initiation of a novel pipeline program, EVX-B3, an artificial intelligence (AI)-designed vaccine candidate against an undisclosed bacterial pathogen. The new vaccine project will be the subject of a co-funded collaboration between Evaxion and an undisclosed partner.

Biontech SE and the Coalition for Epidemic Preparedness Innovations (CEPI) have established a strategic partnership to advance mRNA-based vaccine candidates with the development of BNT-166 for the prevention of mpox (formerly monkeypox).

Dewpoint Therapeutics Inc. and Chemify Ltd. have partnered to develop a suite of digitally discovered and automatically synthesized novel molecules on Chemify’s programmable chemistry platform against condensate targets of interest in Dewpoint’s oncology and neurodegeneration pipeline.

Proteros Biostructures GmbH has established a new collaboration with Orion Corp. The two companies are engaging in a joint multitarget collaboration for early-stage drug discovery projects in oncology and pain using Proteros’ discovery platform, and now have decided to combine their expertise to assemble a chemically diverse small-molecule library collection. The nonexclusive agreement enables Proteros to exclusively offer access to this high throughput screening (HTS) library to all its clients.

Xtalpi Inc. and Parthenon Therapeutics Inc. (now known as Incendia Therapeutics Inc.) have entered into a collaboration to discover novel therapeutic antibodies for the treatment of solid tumors.